• ImmunOs Therapeutics secures funding from both existing and new investors, including Double Point Ventures.
• This investment ensures the continuation of the promising clinical trial for IOS-1002 in treating solid cancers.

September 17, 2024 – ImmunOs Therapeutics AG, a biopharmaceutical company focusing on developing innovative therapies for cancer and autoimmune diseases through its unique HLA-based technology platform, announced the completion of its Series C financing round, raising $11 million. The round was led by existing investors including Gimv, Pfizer Ventures, Mission BioCapital, and BioMed Partners, alongside new investor Double Point Ventures and other existing investors. As part of this funding round, Steve Tregay, PhD, Managing General Partner of Mission BioCapital, has joined the Company’s Board of Directors.

The funds raised from the Series C financing will be utilized to continue the ongoing clinical trial for ImmunOs’ lead program, IOS-1002. This will involve completing the Phase Ia dose escalation clinical trial as a monotherapy and in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab). IOS-1002 is a groundbreaking multifunctional immunotherapy agent designed for advanced solid tumors. It works by simultaneously targeting various immune checkpoints, leveraging a naturally occurring human leukocyte antigen (HLA) that interacts with LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1. This mechanism activates both innate and adaptive immune cells to modify the tumor microenvironment, potentially enhancing the efficacy of existing immunotherapy treatments like KEYTRUDA.

“We are thrilled to finalize this important financing round with both existing and new investors,” stated Reinhard Ambros, Executive Chairman of the Board of ImmunOs Therapeutics. “This investment reflects the strong interest in this field and our promising, differentiated lead program, which holds significant therapeutic potential. The funding allows us to advance our lead program, IOS-1002, both as a monotherapy and in combination with KEYTRUDA. IOS-1002 is the most advanced HLA-based program globally, targeting these crucial checkpoints and offering a novel, multifunctional immunotherapy approach.”

“We are excited to invest in ImmunOs Therapeutics, with its substantial potential as a first-in-class immunotherapy approach for both solid and liquid tumors,” said Campbell Murray, Advisor at Double Point Ventures. “We are looking forward to supporting ImmunOs’ success.”

“We believe that ImmunOs Therapeutics’ unique platform is ideally positioned to deliver potentially innovative approaches in inflammatory diseases and immuno-oncology,” added Michael Baran, Partner at Pfizer Ventures. “We look forward to the opportunity to review clinical data, potentially in 2025.” 

“The Company is well-differentiated in exploiting its potentially first-in-class immunotherapy for the benefit of patients with limited therapeutic options. ImmunOs’ approach of identifying HLA molecules with naturally tailored affinity and specificity profiles is not just elegant but also truly differentiated,” stated Andreas Jurgeit, PhD, Partner at Gimv. “We are extremely excited by the progress being made at ImmunOs and proud to support the team further towards clinical validation for the benefit of patients.”  

“ImmunOs Therapeutics has a very innovative approach to target myeloid checkpoints which are potentially the next major breakthrough in immuno-oncology,” said Steve Tregay, Managing General Partner at Mission BioCapital. “We look forward to enable more exciting data from the clinical trials of IOS-1002.”

ImmunOs Therapeutics is dedicated to advancing the clinical development of IOS-1002 and exploring its potential to enhance the lives of cancer patients.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

###

About ImmunOs Therapeutics AG

ImmunOs Therapeutics AG leverages its unique immune system modulating HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases. ImmunOs’ lead program is a multi-functional HLA-fusion protein that binds specific LILRB (leukocyte immunoglobulin-like) and KIR (killer cell immunoglobulin-like) receptors and can stimulate both the innate and the adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs is also developing different modalities to agonize receptors for the modulation of the immune system in autoimmune diseases.

The Company is supported by leading international investors and is located in Schlieren, Switzerland.  For more information, please visit .

Company Contact
ImmunOs Therapeutics AG
Wagistrasse 18
8952 Schlieren (Zurich Area), Switzerland

Media Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info@akampion.com
Tel. +49 40 88 16 59 64 /
Tel. +49 30 23 63 27 68